Investor’s Business Daily: Upturn In Biotech Spending Drives Covance’s Growth: “Growth in the CRO sector is driven by biopharmaceutical research, development spending and a robust biotech funding environment, which hit $20.1 billion last year.” As large pharmaceutical companies struggle with their cost structures they turn increasingly to outsourcing. Development stage biotechs often choose not to … Continue reading CRO Industry Outlook